Platelet signalling abnormalities in patients with type 2 diabetes mellitus: A review

Blood Cells, Molecules, and Diseases

Volumn 41, Issue 1, 2008, Pages 119-123

  El Haouari, Mohammed ^a   Rosado, Juan A ^b  

^a FACULTÉ DES SCIENCES   (Morocco)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Calcium signalling; Diabetes mellitus; Platelets; Protein phosphorylation; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; BRUTON TYROSINE KINASE; CALCIUM; CYCLIC GMP; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL FREE SYSTEM; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ANOMALY;

ANTIOXIDANTS; BLOOD PLATELETS; CALCIUM SIGNALING; CYCLIC GMP; DIABETES MELLITUS, TYPE 2; HUMANS; NITRIC OXIDE; OXIDATIVE STRESS; PLATELET ACTIVATION; PROTEIN-TYROSINE KINASES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 44449116514     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2008.02.010     Document Type: Article

References (77)

1. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
2. Cimminiello C., and Milani M. Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events?. Diabetologia 39 (1996) 1402-1404
3. Sobol A.B., and Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res. Clin. Pract. 50 (2000) 1-16
4. Guillausseau P.J., Dupuy E., Guillausseau C., Warnet A., Caen J., and Lubetzki J. Hemostasis disorders in diabetes mellitus. Horm. Metab. Res., Suppl. Ser. 15 (1985) 60-62
5. 2+ mobilization and protein tyrosine phosphorylation. J. Appl. Biomed. 5 (2007) 105-113
6. Gabbianelli R., Falcioni G., Dow C.S., Vince F.P., and Swoboda B. A new method to evaluate spontaneous platelet aggregation in type 2 diabetes by Cellfacts. Clin. Chim. Acta 329 (2003) 95-102
7. Holmsen H. Platelet metabolism and activation. Semin. Hematol. 22 (1985) 219-240
8. Andrews R.K., Shen Y., Gardiner E.E., and Berndt M.C. Platelet adhesion receptors and (patho)physiological thrombus formation. Histol. Histopathol. 16 (2001) 969-980
9. Kaibuchi K., Takai Y., Sawamura M., Hoshijima M., Fujikura T., and Nishizuka Y. Synergistic functions of protein phosphorylation and calcium mobilization in platelet activation. J. Biol. Chem. 258 (1983) 6701-6704
10. Rittenhouse S.E. Human platelets contain phospholipase C that hydrolyzes polyphosphoinositides. Proc. Natl. Acad. Sci. 80 (1983) 5417-5420
11. George J.N., Thoi L.L., McManus L.M., and Reimann T.A. Isolation of human platelet membrane microparticles from plasma and serum. Blood 60 (1982) 834-840
12. Miyazaki Y., Nomura S., Miyake T., Kagawa H., Kitada C., Taniguchi H., Komiyama Y., Fujimura Y., Ikeda Y., and Fukuhara S. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 88 (1996) 3456-3464
13. Nomura S. Function and clinical significance of platelet-derived microparticles. Int. J. Hematol. 74 (2001) 397-404
14. Nomura S., Suzuki M., Katsura K., Xie G.L., Miyazaki Y., Miyake T., Kido H., Kagawa H., and Fukuhara S. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 116 (1995) 235-240
15. VanWijk M.J., VanBavel E., Sturk A., and Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc. Res. 59 (2003) 277-287
16. Trovati M., Massucco P., Mattiello L., Piretto V., Cavalot F., Mularoni E., and Anfossi G. The insulin-induced increase of guanosine-3′,5′-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes 45 (1996) 768-770
17. Udvardy M., Pfliegler G., and Rak K. Platelet insulin receptor determination in non-insulin dependent diabetes mellitus. Experientia 41 (1985) 422-423
18. Trovati M., Anfossi G., Cavalot F., Massucco P., Mularoni E., and Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 37 (1988) 780-786
19. Vinik A.I., Erbas T., Park T.S., Nolan R., and Pittenger G.L. Platelet dysfunction in type 2 diabetes. Diabetes Care 24 (2001) 1476-1485
20. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J. Diabetes Its Complicat. 15 (2001) 203-210
21. Chlopicki S., Olszanecki R., Janiszewski M., Laurindo F.R., Panz T., and Miedzobrodzki J. Functional role of NADPH oxidase in activation of platelets. Antioxid. Redox Signal. 6 (2004) 691-698
22. Krotz F., Sohn H.Y., and Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1988-1996
23. Pignatelli P., Sanguigni V., Lenti L., Ferro D., Finocchi A., Rossi P., and Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 110 (2004) 1326-1329
24. Colwell J.A., and Nesto R.W. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26 (2003) 2181-2188
25. Taniyama Y., and Griendling K.K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42 (2003) 1075-1081
26. Leoncini G., Signorello M.G., Piana A., Carrubba M., and Armani U. Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. Thromb. Res. 86 (1997) 153-160
27. Ceriello A. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabet. Nutr. Metab. 12 (1999) 42-46
28. Iuliano L., Colavita A.R., Leo R., Pratico D., and Violi F. Oxygen free radicals and platelet activation. Free Radic. Biol. Med. 22 (1997) 999-1006
29. Seno T., Inoue N., Gao D., Okuda M., Sumi Y., Matsui K., Yamada S., Hirata K.I., Kawashima S., Tawa R., Imajoh-Ohmi S., Sakurai H., and Yokoyama M. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb. Res. 103 (2001) 399-409
30. Wachowicz B., Olas B., Zbikowska H.M., and Buczynski A. Generation of reactive oxygen species in blood platelets. Platelets 13 (2002) 175-182
31. Begonja A.J., Gambaryan S., Geiger J., Aktas B., Pozgajova M., Nieswandt B., and Walter U. Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood 106 (2005) 2757-2760
32. Pignatelli P., Pulcinelli F.M., Lenti L., Gazzaniga P.P., and Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 91 (1998) 484-490
33. Abe J., Takahashi M., Ishida M., Lee J.D., and Berk B.C. c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J. Biol. Chem. 15 (1997) 20389-20394
34. Finkel T. Oxygen radicals and signaling. Curr. Opin. Cell. Biol. 10 (1998) 248-253
35. 2+ entry in human platelets. Cell. Signal. 17 (2005) 1011-1021
36. Morel O., Jesel L., Hugel B., Douchet M.P., Zupan M., Chauvin M., Freyssinet J.M., and Toti F. Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J. Thromb. Haemost. 1 (2003) 171-177
37. Ferroni P., Basili S., Falco A., and Davi G. Platelet activation in type 2 diabetes mellitus. J. Thromb. Haemost. 2 (2004) 1282-1291
38. 2+ homeostasis in diabetes mellitus. Am. J. Physiol, Heart Circ. Physiol. 280 (2001) H1480-H1489
39. 2+ entry. Arch. Biochem. Biophys. 465 (2007) 16-25
40. +-ATPases in human platelets. Biochem. J. 390 (2005) 243-252
41. Rosado J.A., and Sage S.O. The ERK cascade, a new pathway involved in the activation of store-mediated calcium entry in human platelets. Trends Cardiovasc. Med. 12 (2002) 229-234
42. Rosado J.A., and Sage S.O. The actin cytoskeleton in store-mediated calcium entry. J. Physiol. 2 (2000) 221-229
43. 2+ entry and tyrosine kinase pp60(src) hyperactivity are modulated by hyperglycemia in platelets from patients with non insulin-dependent diabetes mellitus. Arch. Biochem. Biophys. 432 (2004) 261-268
44. 2+-ATPase function in platelets from patients with non-insulin-dependent diabetes mellitus. Haematologica 89 (2004) 1142-1144
45. 2+-ATPase expression in diabetes: a novel signature of abnormal megakaryocytopoiesis. J. Thromb. Haemost. 5 (2007) 2127-2135
46. 2+ mobilization and aggregation in platelets from type 2 diabetic patients. Biochem. Biophys. Res. Commun. 333 (2005) 794-802
47. Sargeant P., Farndale R.W., and Sage S.O. The tyrosine kinase inhibitors methyl 2,5-dihydroxycinnamate and genistein reduce thrombin-evoked tyrosine phosphorylation and Ca2+ entry in human platelets. FEBS Lett. 315 (1993) 242-246
48. Sargeant P., Farndale R.W., and Sage S.O. Calcium store depletion in dimethyl BAPTA-loaded human platelets increases protein tyrosine phosphorylation in the absence of a rise in cytosolic calcium. Exp. Physiol. 79 (1994) 269-272
49. Gawaz M., Ott I., Reininger A.J., and Neumann F.J. Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb. Haemost. 72 (1994) 912-918
50. Clark E.A., Shattil S.J., and Brugge J.S. Regulation of protein tyrosine kinases in platelets. Trends Biochem. Sci. 19 (1994) 464-469
51. Coulon L., Calzada C., Moulin P., Vericel E., and Lagarde M. Activation of p38 mitogen-activated protein kinase/cytosolic phospholipase A2 cascade in hydroperoxide-stressed platelets. Free Radic. Biol. Med. 35 (2003) 616-625
52. Salmeen A., Andersen J.N., Myers M.P., Meng T.C., Hinks J.A., Tonks N.K., and Barford D. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423 (2003) 769-773
53. Randriamboavonjy V., and Fleming I. Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there?. Pharmacol. Rep. 57 (2005) 59-65
54. Schafer A., Wiesmann F., Neubauer S., Eigenthaler M., Bauersachs J., and Channon K.M. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation, 109 (2004) 1819-1822
55. Martina V., Bruno G.A., Trucco F., Zumpano E., Tagliabue M., Di Bisceglie C., and Pescarmona G. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb. Haemost. 79 (1998) 520-522
56. Rabini R.A., Staffolani R., Fumelli P., Mutus B., Curatola G., and Mazzanti L. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia 41 (1998) 101-104
57. Chirkov Y., Tyshchuk I.A., and Severina I.S. Guanylate cyclase in human platelets with different aggregability. Experientia 46 (1990) 697-699
58. De La Cruz J.P., Arrebola M.M., Villalobos M.A., Pinacho A., Guerrero A., Gonzalez-Correa J.A., and Sanchez de la Cuesta F. Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur. J. Pharmacol. 484 (2004) 19-27
59. Eigenthaler M., Nolte C., Halbrugge M., and Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur. J. Biochem. 205 (1992) 471-481
60. Horstrup K., Jablonka B., Honig-Liedl P., Just M., Kochsiek K., and Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur. J. Biochem. 225 (1994) 21-27
61. Papanas N., Symeonidis G., Maltezos E., Mavridis G., Karavageli E., Vosnakidis T., and Lakasas G. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 15 (2004) 475-478
62. Hekimsoy Z., Payzin B., Ornek T., and Kandogan G. Mean platelet volume in Type 2 diabetic patients. J. Diabetes Its Complicat. 18 (2004) 173-176
63. Kim S.W., Ryu G.H., Lee I., Koh J.J., Min B.G., and Lee H.K. Adhered platelet morphology in diabetes mellitus. Diabetes Metab. 21 (1995) 50-53
64. Brown A.S., Hong Y., de Belder A., Beacon H., Beeso J., Sherwood R., Edmonds M., Martin J.F., and Erusalimsky J.D. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 802-807
65. Sharpe P.C., and Trinick T. Mean platelet volume in diabetes mellitus. Q. J. Med. 86 (1993) 739-742
66. Tchobroutsky G. Relation of diabetic control to development of microvascular complications. Diabetologia 15 (1978) 143-152
67. Dang A.Q., Faas F.H., Jethmalani S.M., and Carter W.J. Modifications of platelet phospholipid fatty acid composition in streptozocin-induced diabetic rats. Prostaglandins Leukot. Essent. Fat. Acids 47 (1992) 17-22
68. Ceriello A., Taboga C., Giacomello R., Falleti E., De Stasio G., Motz E., Lizzio S., Gonano F., and Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 43 (1994) 430-432
69. Ceriello A., Giacomello R., Stel G., Motz E., Taboga C., Tonutti L., Pirisi M., Falleti E., and Bartoli E. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 44 (1995) 924-928
70. Akai T., Naka K., Okuda K., Takemura T., and Fujii S. Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metab Res. 15 (1983) 523-526
71. Nolan R.D., Platt K.H., and Loose P.G. The resistance to nitric oxide inhibition of platelet aggregation is due to decreased phosphorylation of rap1B in platelets of NIDDM compared with control subjects. Diabetes 43 (1994) 101A
72. Fukuda K., Ozaki Y., Satoh K., Kume S., Tawata M., Onaya T., Sakurada K., Seto M., and Sasaki Y. Phosphorylation of myosin light chain in resting platelets from NIDDM patients is enhanced: correlation with spontaneous aggregation. Diabetes. 46 (1997) 488-493
73. Van Zile J., Kilpatrick M., Laimins M., Sagel J., Colwell J., and Virella G. Platelet aggregation and release of ATP after incubation with soluble immune complexes purified from the serum of diabetic patients. Diabetes 30 (1981) 575-579
74. Garg S.K., Lackner H., and Karpatkin S. The increased percentage of megathrombocytes in various clinical disorders. Ann. Intern. Med. 77 (1972) 361-369
75. Winocour P.D., Watala C., and Kinglough-Rathbone R.L. Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes from diabetic and control subjects. Thromb. Haemost. 67 (1992) 567-571
76. Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin. Thromb. Hemost. 21 (1995) 152-160
77. Geiser T., Sturzenegger M., Genewein U., Haeberli A., and Beer J.H. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke 29 (1998) 1770-1777